MicroRNAs in Parkinson’s Disease: Modulation of Neuronal Survival and Apoptosis

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Apoptosis, or programmed cell death, is a fundamental biological mechanism responsible for eliminating abnormal or unnecessary cells. Over the past decade, the regulation of apoptotic pathways has been extensively investigated as a potential therapeutic target in neurodegenerative disorders, including Parkinson’s disease (PD). PD is characterized by the progressive degeneration of dopaminergic neurons in the substantia nigra, leading to significant motor impairment.

Current therapeutic options, particularly levodopa (L-Dopa), provide symptomatic relief but do not alter the underlying disease progression. Moreover, prolonged use of L-Dopa is associated with adverse effects. Consequently, new therapeutic strategies are being explored, with microRNAs (miRNAs) emerging as promising candidates due to their ability to regulate apoptosis and other critical cellular processes.

Role of miRNAs in Parkinson’s Disease

miRNAs are small, non-coding RNA molecules that regulate gene expression by binding to messenger RNA (mRNA) and influencing protein synthesis. They act as molecular regulators in processes such as proliferation, differentiation, and apoptosis. In the context of PD, miRNAs demonstrate two key functions:

1. Neuroprotection: Certain miRNAs inhibit apoptosis in dopaminergic neurons, thereby preserving neuronal survival.
2. Cell Clearance: Other miRNAs promote apoptosis in dysfunctional or damaged neurons, facilitating removal of cellular debris.

This dual function highlights their potential to both prevent the death of healthy dopamine-producing neurons and support the clearance of pathological cells.

Advantages of miRNA-Based Therapeutics in PD

Several attributes make miRNAs strong candidates for novel treatment strategies:

• Target Specificity: miRNAs can selectively regulate genes directly involved in apoptotic pathways.
• Bidirectional Control: They can activate or inhibit apoptosis depending on cellular needs, a critical factor in balancing neuronal survival and clearance.
• Blood–Brain Barrier Penetration: miRNAs can cross the blood–brain barrier and enter neurons, overcoming a key challenge in neurodegenerative disease therapy.
• Neuroplasticity and Proliferation: Some miRNAs enhance neuronal regeneration and plasticity, supporting long-term functional recovery.
• Delivery Potential: miRNAs can be efficiently transported using extracellular vesicles such as exosomes, providing a natural delivery system.
• Biomarker Utility: Specific miRNAs (e.g., miR-29c, miR-146a, miR-221, miR-214) have been identified in cerebrospinal fluid and blood, offering potential diagnostic and prognostic value.

Inflammation and Neurodegeneration

Chronic neuroinflammation is a critical contributor to PD progression. Microglial overactivation amplifies neuronal injury and accelerates degeneration. miRNAs are closely involved in modulating these inflammatory responses. For example:

• miR-155 enhances pro-inflammatory signaling, worsening α-synuclein–induced neurotoxicity.
• miR-22 supports neuronal survival and proliferation by suppressing pro-inflammatory cascades.

This interplay between miRNAs and microglial activity underscores their relevance in controlling both neurodegeneration and repair mechanisms.

Clinical Potential of miRNAs in PD

Apoptosis of dopaminergic neurons remains the central pathological hallmark of PD, leading to progressive motor impairment. By regulating key apoptotic and inflammatory pathways, miRNAs present a multifaceted therapeutic approach. Their capacity to simultaneously target multiple genes provides an advantage in addressing the complex, multifactorial nature of PD.

Summary of Potential Benefits

• Ability to inhibit or induce apoptosis as required.
• Capacity to cross the blood–brain barrier and act within neurons.
• Enhancement of neuronal plasticity and regeneration.
• Improvement of neuroprotection mechanisms.
• Promotion of neuronal proliferation.
• Use as non-invasive biomarkers for disease detection and monitoring.
• Regulation of microglial activity, thereby reducing chronic neuroinflammation.
• Potential to preserve dopamine-producing neurons and slow disease progression.

Conclusion

miRNAs represent a promising avenue for future therapeutic development in Parkinson’s disease. Their unique capacity to regulate apoptosis, modulate inflammatory responses, and serve as biomarkers positions them as both diagnostic and therapeutic tools. While further research and clinical validation are required, miRNA-based strategies hold the potential to modify disease progression, offering a significant advancement beyond current symptomatic treatments.

REFERENCES

1. Yang, X., Zhang, M., Wei, M. et al. MicroRNA-216a inhibits neuronal apoptosis in a cellular Parkinson’s disease model by targeting Bax. Metab Brain Dis 35, 627–635 (2020). https://doi.org/10.1007/s11011-020-00546-x
2. Alieva, A. K., Filatova, E. V., Karabanov, A. V., Illarioshkin, S. N., Limborska, S. A., Shadrina, M. I., & Slominsky, P. A. (2015). miRNA expression is highly sensitive to a drug therapy in Parkinson’s disease. Parkinsonism & Related Disorders, 21(1), 72-74.
3. Lu, X., Cui, Z., Liu, S., & Yin, F. (2018). MiRNAs participate in the diagnosis, pathogenesis and therapy of Parkinson’s disease.
4. Ma, L., Wei, L., Wu, F., Hu, Z., Liu, Z., & Yuan, W. (2013). Advances with microRNAs in Parkinson’s disease research. Drug design, development and therapy, 1103-1113.
5. Martinez, B., & Peplow, P. V. (2017). MicroRNAs in Parkinson’s disease and emerging therapeutic targets. Neural Regeneration Research, 12(12), 1945-1959.
6. Mouradian, M. M. (2012). MicroRNAs in Parkinson’s disease. Neurobiology of disease, 46(2), 279-284.